Pharvaris N.V.

US$34.39As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:PHVSHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (1.73%)
Div yield —
ROE (70.46%)
Biotechnology
Beta (5Y) (2.52)
PE TTM —
TSR TTM 54.77%
Mkt cap US$2.414B
ROIC (46.85%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$41
18.51%
(57.55%)
Hold 6|6|10|3|10
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.35
0.39
0.42
0.44
22.67%
30.00%
28.21%
27.13%
Revenue€M
154.8
152.0
161.1
162.9
17.60%
13.65%
14.32%
11.14%
Peers (US$2.414B)
Cap (US$)
PE
1.343B
—
2.365B
6.044x
Capital
TTM
5Y
10Y
Leveragex
0.152
0.328
0.360
EBIT/Intx
0.675
0.513
0.484
Own earn%
(49.01)
59.62
34.42
Sh yield%
42.76
31.77
31.60
Owners
Insiders/Inst%
9.51
35.17
Short interest%
1.33
SBC / revenue%
5.89
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
17–23
$1 testx
—
Incr. ROIC%
8